Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer

Journal of Immunology

Volumn 189, Issue 8, 2012, Pages 3936-3946

  Chou, Cassie K ^a   Schietinger, Andrea ^a   Liggitt, H Denny ^a   Tan, Xiaoxia ^a   Funk, Sarah ^a   Freeman, Gordon J ^b   Ratliff, Timothy L ^c   Greenberg, Norman M ^d   Greenberg, Philip D ^a,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PURDUE UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCHTHONOUS PROSTATE CANCER; BIOACCUMULATION; CANCER LOCALIZATION; CANCER MODEL; CD8+ T LYMPHOCYTE; CELL COUNT; CELL SPECIFICITY; CELL THERAPY; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; LYMPHOID ORGAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TARGET CELL;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867298726     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201415     Document Type: Article

References (80)

1. Kantoff, P.W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al; IMPACT Study Investigators. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363: 411-422.
2. Kwek, S. S., E. Cha, and L. Fong. 2012. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat. Rev. Cancer 12: 289-297.
3. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
4. Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. June. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3: 95ra73.
5. Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703. (Pubitemid 351860862)
6. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
7. Berger, C., C. J. Turtle, M. C. Jensen, and S. R. Riddell. 2009. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr. Opin. Immunol. 21: 224-232.
8. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296. (Pubitemid 46697910)
9. Ho, W. Y., J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437. (Pubitemid 38340289)
10. Offringa, R. 2009. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21: 190-199.
11. Schmitt, T. M., G. B. Ragnarsson, and P. D. Greenberg. 2009. T cell receptor gene therapy for cancer. Hum. Gene Ther. 20: 1240-1248.
12. Levéen, P., J. Larsson, M. Ehinger, C. M. Cilio, M. Sundler, L. J. Sjöstrand, R. Holmdahl, and S. Karlsson. 2002. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100: 560-568.
13. Li, M. O., S. Sanjabi, and R. A. Flavell. 2006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471. (Pubitemid 44354214)
14. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
15. Flavell, R. A., S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limón. 2010. The polarization of immune cells in the tumour environment by TGFβ. Nat. Rev. Immunol. 10: 554-567.
16. Pu, H., J. Collazo, E. Jones, D. Gayheart, S. Sakamoto, A. Vogt, B. Mitchell, and N. Kyprianou. 2009. Dysfunctional transforming growth factor-β receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res. 69: 7366-7374.
17. Massagué, J. 2008. TGFβ in cancer. Cell 134: 215-230.
18. Ewen, M. E., H. K. Sluss, L. L. Whitehouse, and D. M. Livingston. 1993. TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74: 1009-1020. (Pubitemid 23289458)
19. Wolfraim, L. A., T. M. Walz, Z. James, T. Fernandez, and J. J. Letterio. 2004. p21Cip1 and p27Kip1 act in synergy to alter the sensitivity of naive T cells to TGF-β-mediated G1 arrest through modulation of IL-2 responsiveness. J. Immunol. 173: 3093-3102. (Pubitemid 39142015)
20. Kehrl, J. H., L. M. Wakefield, A. B. Roberts, S. Jakowlew, M. Alvarez-Mon, R. Derynck, M. B. Sporn, and A. S. Fauci. 1986. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163: 1037-1050. (Pubitemid 16000407)
21. Donkor, M. K., A. Sarkar, P. A. Savage, R. A. Franklin, L. K. Johnson, A. A. Jungbluth, J. P. Allison, and M. O. Li. 2011. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35: 123-134.
22. Thomas, D. A., and J. Massagué. 2005. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
23. Pennison, M., and B. Pasche. 2007. Targeting transforming growth factor-β signaling. Curr. Opin. Oncol. 19: 579-585. (Pubitemid 47508864)
24. Elkord, E. 2007. Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Dis. 10: 224-236. (Pubitemid 47351401)
25. Barrack, E. R. 1997. TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31: 61-70. (Pubitemid 27172044)
26. Lee, C., S. M. Sintich, E. P. Mathews, A. H. Shah, S. D. Kundu, K. T. Perry, J. S. Cho, K. Y. Ilio, M. V. Cronauer, L. Janulis, and J. A. Sensibar. 1999. Transforming growth factor-β in benign and malignant prostate. Prostate 39: 285-290. (Pubitemid 29244503)
27. Diener, K. R., A. E. Woods, J. Manavis, M. P. Brown, and J. D. Hayball. 2009. Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab. Invest. 89: 142-151.
28. Gorelik, L., and R. A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7: 1118-1122.
29. Zhang, Q., T. L. Jang, X. Yang, I. Park, R. E. Meyer, S. Kundu, M. Pins, B. Javonovic, T. Kuzel, S. J. Kim, et al. 2006. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 66: 235-247. (Pubitemid 43191223)
30. Zhang, Q., X. Yang, M. Pins, B. Javonovic, T. Kuzel, S. J. Kim, L. V. Parijs, N. M. Greenberg, V. Liu, Y. Guo, and C. Lee. 2005. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65: 1761-1769. (Pubitemid 40478602)
31. Willimsky, G., and T. Blankenstein. 2007. The adaptive immune response to sporadic cancer. Immunol. Rev. 220: 102-112. (Pubitemid 350045578)
32. Greenberg, N. M., F. DeMayo, M. J. Finegold, D. Medina, W. D. Tilley, J. O. Aspinall, G. R. Cunha, A. A. Donjacour, R. J. Matusik, and J. M. Rosen. 1995. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443.
33. Kaplan-Lefko, P. J., T. M. Chen, M. M. Ittmann, R. J. Barrios, G. E. Ayala, W. J. Huss, L. A. Maddison, B. A. Foster, and N. M. Greenberg. 2003. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237. (Pubitemid 36532401)
34. Hsu, C. X., B. D. Ross, C. E. Chrisp, S. Z. Derrow, L. G. Charles, K. J. Pienta, N. M. Greenberg, Z. Zeng, and M. G. Sanda. 1998. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J. Urol. 160: 1500-1505. (Pubitemid 29480568)
35. Lees, J. R., B. Charbonneau, J. D. Hayball, K. Diener, M. Brown, R. Matusik, M. B. Cohen, and T. L. Ratliff. 2006. T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate 66: 578-590.
36. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. (Pubitemid 24035278)
37. Zhang, D. J., Q. Wang, J. Wei, G. Baimukanova, F. Buchholz, A. F. Stewart, X. Mao, and N. Killeen. 2005. Selective expression of the Cre recombinase in late-stage thymocytes using the distal promoter of the Lck gene. J. Immunol. 174: 6725-6731. (Pubitemid 40705634)
38. Keir, M. E., Y. E. Latchman, G. J. Freeman, and A. H. Sharpe. 2005. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 175: 7372-7379. (Pubitemid 41713434)
39. Rodig, N., T. Ryan, J. A. Allen, H. Pang, N. Grabie, T. Chernova, E. A. Greenfield, S. C. Liang, A. H. Sharpe, A. H. Lichtman, and G. J. Freeman. 2003. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33: 3117-3126. (Pubitemid 37428344)
40. Akbari, O., P. Stock, A. K. Singh, V. Lombardi, W. L. Lee, G. J. Freeman, A. H. Sharpe, D. T. Umetsu, and R. H. Dekruyff. 2010. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 3: 81-91.
41. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. (Pubitemid 43237609)
42. Wildey, G. M., and P. H. Howe. 2009. Runx1 is a co-activator with FOXO3 to mediate transforming growth factor β (TGFβ)-induced Bim transcription in hepatic cells. J. Biol. Chem. 284: 20227-20239.
43. Tinoco, R., V. Alcalde, Y. Yang, K. Sauer, and E. I. Zuniga. 2009. Cell-intrinsic transforming growth factor-β signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 31: 145-157.
44. Barth, R. J., Jr., J. J. Mulé, P. J. Spiess, and S. A. Rosenberg. 1991. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173: 647-658.
45. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111. (Pubitemid 32391043)
46. Dissanayake, D., M. A. Gronski, A. Lin, A. R. Elford, and P. S. Ohashi. 2011. Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. Immunol. Rev. 241: 164-179.
47. Garrido, F., T. Cabrera, and N. Aptsiauri. 2010. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 127: 249-256.
48. Nanda, N. K., L. Birch, N. M. Greenberg, and G. S. Prins. 2006. MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment. Prostate 66: 1275-1284. (Pubitemid 44384304)
49. Mueller, S. N., and R. Ahmed. 2009. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 106: 8623-8628.
50. Bucks, C. M., J. A. Norton, A. C. Boesteanu, Y. M. Mueller, and P. D. Katsikis. 2009. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 182: 6697-6708.
51. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77: 4911-4927. (Pubitemid 36402840)
52. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
53. Sfanos, K. S., T. C. Bruno, A. K. Meeker, A. M. De Marzo, W. B. Isaacs, and C. G. Drake. 2009. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 69: 1694-1703.
54. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704. (Pubitemid 351600389)
55. Crane, C. A., A. Panner, J. C. Murray, S. P. Wilson, H. Xu, L. Chen, J. P. Simko, F. M. Waldman, R. O. Pieper, and A. T. Parsa. 2009. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 28: 306-312.
56. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207: 2187-2194.
57. Woo, S. R., M. E. Turnis, M. V. Goldberg, J. Bankoti, M. Selby, C. J. Nirschl, M. L. Bettini, D. M. Gravano, P. Vogel, C. L. Liu, et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72: 917-927.
58. Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28: 3167-3175.
59. Berger, R., R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, and A. Nagler. 2008. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14: 3044-3051.
60. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
61. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
62. Bai, A., E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen. 2008. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. USA 105: 13003-13008.
63. Blackburn, S. D., H. Shin, G. J. Freeman, and E. J. Wherry. 2008. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc. Natl. Acad. Sci. USA 105: 15016-15021.
64. Hurwitz, A. A., B. A. Foster, E. D. Kwon, T. Truong, E. M. Choi, N. M. Greenberg, M. B. Burg, and J. P. Allison. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60: 2444-2448. (Pubitemid 30262435)
65. Grosso, J. F., C. C. Kelleher, T. J. Harris, C. H. Maris, E. L. Hipkiss, A. De Marzo, R. Anders, G. Netto, D. Getnet, T. C. Bruno, et al. 2007. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 117: 3383-3392. (Pubitemid 350096994)
66. West, E. E., B. Youngblood, W. G. Tan, H. T. Jin, K. Araki, G. Alexe, B. T. Konieczny, S. Calpe, G. J. Freeman, C. Terhorst, et al. 2011. Tight regulation of memory CD8+ T cells limits their effectiveness during sustained high viral load. Immunity 35: 285-298.
67. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64. (Pubitemid 32368029)
68. Watkins, S. K., Z. Zhu, E. Riboldi, K. A. Shafer-Weaver, K. E. Stagliano, M. M. Sklavos, S. Ambs, H. Yagita, and A. A. Hurwitz. 2011. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121: 1361-1372.
69. Anderson, M. J., K. Shafer-Weaver, N. M. Greenberg, and A. A. Hurwitz. 2007. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J. Immunol. 178: 1268-1276. (Pubitemid 46154596)
70. Higham, E. M., C. H. Shen, K. D. Wittrup, and J. Chen. 2010. Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. J. Immunol. 184: 5954-5958.
71. Hess Michelini, R., M. Freschi, T. Manzo, E. Jachetti, E. Degl'Innocenti, M. Grioni, V. Basso, C. Bonini, E. Simpson, A. Mondino, and M. Bellone. 2010. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res. 70: 3505-3514.
72. Degl'Innocenti, E., M. Grioni, G. Capuano, E. Jachetti, M. Freschi, M. T. Bertilaccio, R. Hess-Michelini, C. Doglioni, and M. Bellone. 2008. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res. 68: 292-300.
73. Kim, J. M., J. P. Rasmussen, and A. Y. Rudensky. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8: 191-197. (Pubitemid 46152650)
74. Baitsch, L., P. Baumgaertner, E. Devêvre, S. K. Raghav, A. Legat, L. Barba, S. Wieckowski, H. Bouzourene, B. Deplancke, P. Romero, et al. 2011. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121: 2350-2360.
75. Wada, S., K. Yoshimura, E. L. Hipkiss, T. J. Harris, H. R. Yen, M. V. Goldberg, J. F. Grosso, D. Getnet, A. M. Demarzo, G. J. Netto, et al. 2009. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 69: 4309-4318.
76. Harris, T. J., E. L. Hipkiss, S. Borzillary, S. Wada, J. F. Grosso, H. R. Yen, D. Getnet, T. C. Bruno, M. V. Goldberg, D. M. Pardoll, et al. 2008. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 68: 1319-1329.
77. Schietinger, A., J. J. Delrow, R. S. Basom, J. N. Blattman, and P. D. Greenberg. 2012. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335: 723-727.
78. Schietinger, A., M. Philip, and H. Schreiber. 2008. Specificity in cancer immunotherapy. Semin. Immunol. 20: 276-285.
79. Savage, P. A., K. Vosseller, C. Kang, K. Larimore, E. Riedel, K. Wojnoonski, A. A. Jungbluth, and J. P. Allison. 2008. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319: 215-220.
80. Fassò, M., R. Waitz, Y. Hou, T. Rim, N. M. Greenberg, N. Shastri, L. Fong, and J. P. Allison. 2008. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc. Natl. Acad. Sci. USA 105: 3509-3514.